Biotech Layoffs
Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift
Biogen; AAV gene therapy; layoffs; staff reorganization; biotech layoffs; pharma restructuring; gene therapy discontinuation
Fierce Biotech Layoff Tracker 2025: Abata Folds; Generation Lays Off 90% of Staff
biotech layoffs; Abata; Generation; Fierce Biotech Layoff Tracker; 2025; company closure; staff reduction
Biotech Layoff Wave Hits Karyopharm, Century, and Pacira in 2025
biotech layoffs; Karyopharm Therapeutics; Century Therapeutics; Pacira; 2025 workforce reductions; biopharma restructuring
Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options
Leap Therapeutics; workforce reduction; biotech layoffs; clinical trial; strategic alternatives; sirexatamab; FL-501; R&D wind down
Recursion and Genentech Announce Significant Staff Layoffs in 2025
Recursion Pharmaceuticals; Genentech; biotech layoffs; workforce reduction; pipeline cutbacks; biotech funding; pharmaceutical industry; 2025 layoffs
Struggling Biotechs Face Harsh Market as Funding and Clinical Successes Dry Up in 2025
biotech layoffs; market downturn; funding challenges; clinical trial failures; investor sentiment; M&A slowdown; job cuts; biotech sector
Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures
Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology
AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil
Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs
Biotech Layoffs Continue in 2024: Spero and Pfizer Among Latest to Cut Workforce
Biotech layoffs, Spero, Pfizer, workforce reduction, 2024 layoffs, pharmaceutical industry, job cuts.
Spero Therapeutics Slashes 39% of Workforce Following Phase 2 Antibiotic Trial Failure
Spero Therapeutics, antibiotic trial failure, workforce reduction, biotech layoffs, cash runway extension